Estrogen receptors regulate galectin‑3 in androgen‑independent DU‑145 prostate cancer cells

The aim of the present study was to investigate the role of estrogen receptor (ER)α and ERβ, and galectin‑3 (GAL‑3) in migration and invasion of androgen‑independent DU‑145 prostate cancer cells, and to examine the regulation of the expression of GAL‑3 by the activation of these receptors. Wound hea...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncology reports 2023-05, Vol.49 (5), p.1, Article 93
Hauptverfasser: Souza, Deborah S, Macheroni, Carla, Vicente, Carolina M, Cavalheiro, Renan P, Campo, Vanessa L, Porto, Catarina S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 5
container_start_page 1
container_title Oncology reports
container_volume 49
creator Souza, Deborah S
Macheroni, Carla
Vicente, Carolina M
Cavalheiro, Renan P
Campo, Vanessa L
Porto, Catarina S
description The aim of the present study was to investigate the role of estrogen receptor (ER)α and ERβ, and galectin‑3 (GAL‑3) in migration and invasion of androgen‑independent DU‑145 prostate cancer cells, and to examine the regulation of the expression of GAL‑3 by the activation of these receptors. Wound healing and cell invasion assays were performed using the control (basal level of cellular function) and treated DU‑145 cells. At 24 h of treatment, 17β‑estradiol (E2), the ERα‑selective agonist, 4,4',4"‑(4‑propyl‑(1H)‑pyrazole‑1,3,5‑triyl)trisphenol (PPT), or the ERβ‑selective agonist, 2,3‑bis(4‑hydroxyphenyl)‑propionitrile (diarylprepionitrile; DPN), increased the migration and invasion of the DU‑145 cells. Pre‑treatment with the ERα‑ and ERβ‑selective antagonists blocked these effects, indicating that ERα and ERβ are upstream receptors regulating these processes. Western blot analysis and immunofluorescence staining for the detection of the GAL‑3 were performed using the control and treated DU‑145 cells. Treatment of the DU‑145 cells with E2, PPT or DPN for 24 h increased the expression of the GAL‑3 compared to the control. Furthermore, a specific inhibitor of GAL‑3 (VA03) inhibited the migration and invasion of DU‑145 cells, indicating the involvement of the complex ERα/GAL‑3 and ERβ/GAL‑3 in the regulation of these processes. On the whole, the present study demonstrates that the activation of both ERs increases the expression and signaling of GAL‑3, and promotes the migration and invasion of DU‑145 cells. The findings of the present study provide novel insight into the signatures and molecular mechanisms of ERα and ERβ in DU‑145 cells.
doi_str_mv 10.3892/or.2023.8530
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10086566</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A749550298</galeid><sourcerecordid>A749550298</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-dfb629d832a132415b2cf36239a286c0bca3b3eba617a9a0d0b19e950cc300f3</originalsourceid><addsrcrecordid>eNptks9rFTEQxxdRbK3ePMuCIB7c5yTZZDenUmq1QsFLBW8hm519L2VfsiZZobf-C_0X-5eYtT_sEwkkk8lnJplvpiheE1ixVtKPPqwoULZqOYMnxT5pJKlozcjTbAMlFWP8x17xIsYLANqAkM-LPSakgFbU-4U-iSn4NboyoMEp-RCztZ5HnbBc6xFNsu7m6pqV1pXa9X_YvLeuxwnz5FL56Xt2kJqXU_AxLYFGO4OhNDiO8WXxbNBjxFd360Fx_vnk_Pi0Ovv25evx0VllOCGp6odOUNm3jGrCaE14R83ABGVS01YY6IxmHcNOC9JoqaGHjkiUHIxhAAM7KA5v005zt8Xe5IcFPaop2K0Ol8prq3ZPnN2otf-lCGQluBA5w_u7DMH_nDEmtbVxKUE79HNUNCvLRENrmdG3_6AXfg4ul6doC21dS06av9Sio7Ju8PlisyRVR01GOFDZZmr1HyqPHrfWeIeDzf6dgHePAjaox7SJfpyT9S7ugh9uQZP_JQYcHtQgoJbeUT6opXfU0jsZf_NYwQf4vlnYb9sfwMM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2808449517</pqid></control><display><type>article</type><title>Estrogen receptors regulate galectin‑3 in androgen‑independent DU‑145 prostate cancer cells</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Souza, Deborah S ; Macheroni, Carla ; Vicente, Carolina M ; Cavalheiro, Renan P ; Campo, Vanessa L ; Porto, Catarina S</creator><creatorcontrib>Souza, Deborah S ; Macheroni, Carla ; Vicente, Carolina M ; Cavalheiro, Renan P ; Campo, Vanessa L ; Porto, Catarina S</creatorcontrib><description>The aim of the present study was to investigate the role of estrogen receptor (ER)α and ERβ, and galectin‑3 (GAL‑3) in migration and invasion of androgen‑independent DU‑145 prostate cancer cells, and to examine the regulation of the expression of GAL‑3 by the activation of these receptors. Wound healing and cell invasion assays were performed using the control (basal level of cellular function) and treated DU‑145 cells. At 24 h of treatment, 17β‑estradiol (E2), the ERα‑selective agonist, 4,4',4"‑(4‑propyl‑(1H)‑pyrazole‑1,3,5‑triyl)trisphenol (PPT), or the ERβ‑selective agonist, 2,3‑bis(4‑hydroxyphenyl)‑propionitrile (diarylprepionitrile; DPN), increased the migration and invasion of the DU‑145 cells. Pre‑treatment with the ERα‑ and ERβ‑selective antagonists blocked these effects, indicating that ERα and ERβ are upstream receptors regulating these processes. Western blot analysis and immunofluorescence staining for the detection of the GAL‑3 were performed using the control and treated DU‑145 cells. Treatment of the DU‑145 cells with E2, PPT or DPN for 24 h increased the expression of the GAL‑3 compared to the control. Furthermore, a specific inhibitor of GAL‑3 (VA03) inhibited the migration and invasion of DU‑145 cells, indicating the involvement of the complex ERα/GAL‑3 and ERβ/GAL‑3 in the regulation of these processes. On the whole, the present study demonstrates that the activation of both ERs increases the expression and signaling of GAL‑3, and promotes the migration and invasion of DU‑145 cells. The findings of the present study provide novel insight into the signatures and molecular mechanisms of ERα and ERβ in DU‑145 cells.</description><identifier>ISSN: 1021-335X</identifier><identifier>EISSN: 1791-2431</identifier><identifier>DOI: 10.3892/or.2023.8530</identifier><identifier>PMID: 36960864</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>Androgens ; Antibodies ; Apoptosis ; Biological products industry ; Cancer cells ; Cancer therapies ; Cell culture ; Estradiol ; Estradiol - pharmacology ; Estrogen Receptor alpha - metabolism ; Estrogen Receptor beta - genetics ; Estrogen Receptor beta - metabolism ; Estrogens ; Experiments ; Galectin 3 ; Humans ; Kinases ; Laboratories ; Male ; Metastasis ; Phenols ; Photographic industry ; Prostate cancer ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - metabolism ; Proteins ; Receptors, Estrogen ; Transcription factors ; Wound healing</subject><ispartof>Oncology reports, 2023-05, Vol.49 (5), p.1, Article 93</ispartof><rights>COPYRIGHT 2023 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2023</rights><rights>Copyright: © Souza et al. 2023</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c511t-dfb629d832a132415b2cf36239a286c0bca3b3eba617a9a0d0b19e950cc300f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,782,786,887,27933,27934</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36960864$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Souza, Deborah S</creatorcontrib><creatorcontrib>Macheroni, Carla</creatorcontrib><creatorcontrib>Vicente, Carolina M</creatorcontrib><creatorcontrib>Cavalheiro, Renan P</creatorcontrib><creatorcontrib>Campo, Vanessa L</creatorcontrib><creatorcontrib>Porto, Catarina S</creatorcontrib><title>Estrogen receptors regulate galectin‑3 in androgen‑independent DU‑145 prostate cancer cells</title><title>Oncology reports</title><addtitle>Oncol Rep</addtitle><description>The aim of the present study was to investigate the role of estrogen receptor (ER)α and ERβ, and galectin‑3 (GAL‑3) in migration and invasion of androgen‑independent DU‑145 prostate cancer cells, and to examine the regulation of the expression of GAL‑3 by the activation of these receptors. Wound healing and cell invasion assays were performed using the control (basal level of cellular function) and treated DU‑145 cells. At 24 h of treatment, 17β‑estradiol (E2), the ERα‑selective agonist, 4,4',4"‑(4‑propyl‑(1H)‑pyrazole‑1,3,5‑triyl)trisphenol (PPT), or the ERβ‑selective agonist, 2,3‑bis(4‑hydroxyphenyl)‑propionitrile (diarylprepionitrile; DPN), increased the migration and invasion of the DU‑145 cells. Pre‑treatment with the ERα‑ and ERβ‑selective antagonists blocked these effects, indicating that ERα and ERβ are upstream receptors regulating these processes. Western blot analysis and immunofluorescence staining for the detection of the GAL‑3 were performed using the control and treated DU‑145 cells. Treatment of the DU‑145 cells with E2, PPT or DPN for 24 h increased the expression of the GAL‑3 compared to the control. Furthermore, a specific inhibitor of GAL‑3 (VA03) inhibited the migration and invasion of DU‑145 cells, indicating the involvement of the complex ERα/GAL‑3 and ERβ/GAL‑3 in the regulation of these processes. On the whole, the present study demonstrates that the activation of both ERs increases the expression and signaling of GAL‑3, and promotes the migration and invasion of DU‑145 cells. The findings of the present study provide novel insight into the signatures and molecular mechanisms of ERα and ERβ in DU‑145 cells.</description><subject>Androgens</subject><subject>Antibodies</subject><subject>Apoptosis</subject><subject>Biological products industry</subject><subject>Cancer cells</subject><subject>Cancer therapies</subject><subject>Cell culture</subject><subject>Estradiol</subject><subject>Estradiol - pharmacology</subject><subject>Estrogen Receptor alpha - metabolism</subject><subject>Estrogen Receptor beta - genetics</subject><subject>Estrogen Receptor beta - metabolism</subject><subject>Estrogens</subject><subject>Experiments</subject><subject>Galectin 3</subject><subject>Humans</subject><subject>Kinases</subject><subject>Laboratories</subject><subject>Male</subject><subject>Metastasis</subject><subject>Phenols</subject><subject>Photographic industry</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - metabolism</subject><subject>Proteins</subject><subject>Receptors, Estrogen</subject><subject>Transcription factors</subject><subject>Wound healing</subject><issn>1021-335X</issn><issn>1791-2431</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptks9rFTEQxxdRbK3ePMuCIB7c5yTZZDenUmq1QsFLBW8hm519L2VfsiZZobf-C_0X-5eYtT_sEwkkk8lnJplvpiheE1ixVtKPPqwoULZqOYMnxT5pJKlozcjTbAMlFWP8x17xIsYLANqAkM-LPSakgFbU-4U-iSn4NboyoMEp-RCztZ5HnbBc6xFNsu7m6pqV1pXa9X_YvLeuxwnz5FL56Xt2kJqXU_AxLYFGO4OhNDiO8WXxbNBjxFd360Fx_vnk_Pi0Ovv25evx0VllOCGp6odOUNm3jGrCaE14R83ABGVS01YY6IxmHcNOC9JoqaGHjkiUHIxhAAM7KA5v005zt8Xe5IcFPaop2K0Ol8prq3ZPnN2otf-lCGQluBA5w_u7DMH_nDEmtbVxKUE79HNUNCvLRENrmdG3_6AXfg4ul6doC21dS06av9Sio7Ju8PlisyRVR01GOFDZZmr1HyqPHrfWeIeDzf6dgHePAjaox7SJfpyT9S7ugh9uQZP_JQYcHtQgoJbeUT6opXfU0jsZf_NYwQf4vlnYb9sfwMM</recordid><startdate>20230501</startdate><enddate>20230501</enddate><creator>Souza, Deborah S</creator><creator>Macheroni, Carla</creator><creator>Vicente, Carolina M</creator><creator>Cavalheiro, Renan P</creator><creator>Campo, Vanessa L</creator><creator>Porto, Catarina S</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230501</creationdate><title>Estrogen receptors regulate galectin‑3 in androgen‑independent DU‑145 prostate cancer cells</title><author>Souza, Deborah S ; Macheroni, Carla ; Vicente, Carolina M ; Cavalheiro, Renan P ; Campo, Vanessa L ; Porto, Catarina S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-dfb629d832a132415b2cf36239a286c0bca3b3eba617a9a0d0b19e950cc300f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Androgens</topic><topic>Antibodies</topic><topic>Apoptosis</topic><topic>Biological products industry</topic><topic>Cancer cells</topic><topic>Cancer therapies</topic><topic>Cell culture</topic><topic>Estradiol</topic><topic>Estradiol - pharmacology</topic><topic>Estrogen Receptor alpha - metabolism</topic><topic>Estrogen Receptor beta - genetics</topic><topic>Estrogen Receptor beta - metabolism</topic><topic>Estrogens</topic><topic>Experiments</topic><topic>Galectin 3</topic><topic>Humans</topic><topic>Kinases</topic><topic>Laboratories</topic><topic>Male</topic><topic>Metastasis</topic><topic>Phenols</topic><topic>Photographic industry</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - metabolism</topic><topic>Proteins</topic><topic>Receptors, Estrogen</topic><topic>Transcription factors</topic><topic>Wound healing</topic><toplevel>online_resources</toplevel><creatorcontrib>Souza, Deborah S</creatorcontrib><creatorcontrib>Macheroni, Carla</creatorcontrib><creatorcontrib>Vicente, Carolina M</creatorcontrib><creatorcontrib>Cavalheiro, Renan P</creatorcontrib><creatorcontrib>Campo, Vanessa L</creatorcontrib><creatorcontrib>Porto, Catarina S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Souza, Deborah S</au><au>Macheroni, Carla</au><au>Vicente, Carolina M</au><au>Cavalheiro, Renan P</au><au>Campo, Vanessa L</au><au>Porto, Catarina S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Estrogen receptors regulate galectin‑3 in androgen‑independent DU‑145 prostate cancer cells</atitle><jtitle>Oncology reports</jtitle><addtitle>Oncol Rep</addtitle><date>2023-05-01</date><risdate>2023</risdate><volume>49</volume><issue>5</issue><spage>1</spage><pages>1-</pages><artnum>93</artnum><issn>1021-335X</issn><eissn>1791-2431</eissn><abstract>The aim of the present study was to investigate the role of estrogen receptor (ER)α and ERβ, and galectin‑3 (GAL‑3) in migration and invasion of androgen‑independent DU‑145 prostate cancer cells, and to examine the regulation of the expression of GAL‑3 by the activation of these receptors. Wound healing and cell invasion assays were performed using the control (basal level of cellular function) and treated DU‑145 cells. At 24 h of treatment, 17β‑estradiol (E2), the ERα‑selective agonist, 4,4',4"‑(4‑propyl‑(1H)‑pyrazole‑1,3,5‑triyl)trisphenol (PPT), or the ERβ‑selective agonist, 2,3‑bis(4‑hydroxyphenyl)‑propionitrile (diarylprepionitrile; DPN), increased the migration and invasion of the DU‑145 cells. Pre‑treatment with the ERα‑ and ERβ‑selective antagonists blocked these effects, indicating that ERα and ERβ are upstream receptors regulating these processes. Western blot analysis and immunofluorescence staining for the detection of the GAL‑3 were performed using the control and treated DU‑145 cells. Treatment of the DU‑145 cells with E2, PPT or DPN for 24 h increased the expression of the GAL‑3 compared to the control. Furthermore, a specific inhibitor of GAL‑3 (VA03) inhibited the migration and invasion of DU‑145 cells, indicating the involvement of the complex ERα/GAL‑3 and ERβ/GAL‑3 in the regulation of these processes. On the whole, the present study demonstrates that the activation of both ERs increases the expression and signaling of GAL‑3, and promotes the migration and invasion of DU‑145 cells. The findings of the present study provide novel insight into the signatures and molecular mechanisms of ERα and ERβ in DU‑145 cells.</abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>36960864</pmid><doi>10.3892/or.2023.8530</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1021-335X
ispartof Oncology reports, 2023-05, Vol.49 (5), p.1, Article 93
issn 1021-335X
1791-2431
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10086566
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Androgens
Antibodies
Apoptosis
Biological products industry
Cancer cells
Cancer therapies
Cell culture
Estradiol
Estradiol - pharmacology
Estrogen Receptor alpha - metabolism
Estrogen Receptor beta - genetics
Estrogen Receptor beta - metabolism
Estrogens
Experiments
Galectin 3
Humans
Kinases
Laboratories
Male
Metastasis
Phenols
Photographic industry
Prostate cancer
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - metabolism
Proteins
Receptors, Estrogen
Transcription factors
Wound healing
title Estrogen receptors regulate galectin‑3 in androgen‑independent DU‑145 prostate cancer cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-29T23%3A39%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Estrogen%20receptors%20regulate%20galectin%E2%80%913%20in%20androgen%E2%80%91independent%20DU%E2%80%91145%20prostate%20cancer%20cells&rft.jtitle=Oncology%20reports&rft.au=Souza,%20Deborah%20S&rft.date=2023-05-01&rft.volume=49&rft.issue=5&rft.spage=1&rft.pages=1-&rft.artnum=93&rft.issn=1021-335X&rft.eissn=1791-2431&rft_id=info:doi/10.3892/or.2023.8530&rft_dat=%3Cgale_pubme%3EA749550298%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2808449517&rft_id=info:pmid/36960864&rft_galeid=A749550298&rfr_iscdi=true